Given the above, physiologically, FATE1 decreases mitochondrial Ca2+ uptake, while its overexpression increases the resistance of adrenocortical cells to apoptosis, even if induced by mitotane treatment, a drug commonly used in the therapy of advanced adrenocortical carcinoma [132]. This evidence concerns the gene FATE1 and adrenal cortex carcinoma.